Autolus Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
AUCATZYL (obe-cel) demonstrates strong efficacy and safety in relapsed/refractory ALL, with expanding U.S. and U.K. market presence and robust real-world results. Ongoing trials target broader patient groups, including frontline and pediatric populations, while margin improvements and scalable manufacturing support future growth.
-
Obe-cel CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in both clinical trials and real-world settings for adult and pediatric ALL, enabling broader patient access and reducing reliance on transplantation. Ongoing studies aim to expand its use to frontline consolidation, with promising early results and increasing adoption across treatment centers.
-
Obe-cel achieved rapid market leadership in relapsed/refractory adult acute leukemia, with strong safety and efficacy data supporting expansion into pediatric, lupus nephritis, and progressive MS indications. Manufacturing optimization and broad U.S. center reach underpin growth, with pivotal study milestones expected through 2028.
Fiscal Year 2025
-
AUCATZYL generated $74.3M in 2025 revenue with strong real-world efficacy and safety, and 2026 guidance targets $120–$135M with positive gross margins. Expansion into new indications and markets is underway, with cash runway into Q4 2027.
-
Aucatzyl (OBE-cel) is now active in over 60 centers with strong sales and robust clinical data, including a 77% remission rate and durable responses. Expansion efforts target new indications in pediatrics and autoimmune diseases, while operational efficiency and market share growth remain key priorities.
-
AUCATZYL achieved U.S. market leadership in relapsed/refractory B-ALL with $21.1M Q3 revenue and broad access, while pipeline expansion and operational optimization are underway. Cash reserves of $367.4M support ongoing pivotal trials, with margin improvements expected as volumes rise.
-
Q2 product sales reached $20.9M, with strong U.S. uptake and expanding center network. Net loss narrowed to $47.9M, and cash reserves remain robust. EU launches are delayed due to reimbursement challenges, while new studies in autoimmune and pediatric indications advance.
-
Obe-cel (AUCATZYL) launched in the U.S. with strong initial uptake, targeting 60 centers and 90%+ patient coverage by year-end. Expansion into Europe and new indications (lupus nephritis, MS) is underway, with a focus on severe unmet needs and efficient development.
-
AUCATZYL (obe-cel) launched with strong momentum, differentiated by its safety profile and broadening access across U.S. centers. Expansion into pediatric ALL and autoimmune indications is underway, with pivotal lupus nephritis and exploratory MS trials planned.
-
Q1 2025 saw $9M in revenue from a strong U.S. launch, rapid center onboarding, and broad payer coverage. Cash reserves remain robust at $516.6M, supporting expansion into Europe and pivotal trials in autoimmune diseases. Deferred revenue and cost of sales reflect early-stage launch dynamics.
-
Obe-cel CAR T therapy shows promising efficacy and safety in severe lupus nephritis, with 50% of early patients achieving complete renal response and significant steroid reduction. A pivotal phase II trial is set to start globally, while expansion into MS and other indications is underway, supported by strong financials and regulatory progress.
-
Aucatzyl's U.S. launch is progressing well, with broad center activation and strong clinical feedback. European approvals are expected in the second half of the year, and early autoimmune data will be presented soon. The company maintains over $500 million in cash, supporting ongoing expansion.
-
Obe-cel's US launch is progressing rapidly, with strong safety and efficacy driving adoption in academic centers. Expansion into new oncology and autoimmune indications is underway, supported by robust manufacturing capabilities and upcoming clinical data presentations.
Fiscal Year 2024
-
2024 saw a successful U.S. launch of AUCATZYL, strong financial positioning with $588M in cash, and rapid center onboarding covering 60% of the target population. Regulatory filings in the U.K. and EU are underway, and pipeline expansion continues, with key data updates expected in 2025.
-
Aucatzyl received early U.S. approval with a strong safety and efficacy profile, no REMS requirement, and a premium but justified price. U.S. launch targets 60 centers by next year, with European launches and key data updates in SLE and pediatric programs expected in 2025.
-
FDA approval of AUCATZYL marks a major milestone, with 30 centers ready for launch and robust manufacturing in place. Cash reserves of $657.1M support commercialization and pipeline expansion, with European approval expected mid-2025.
-
FDA approved Aucatzyl for adult relapsed/refractory B-ALL, based on strong efficacy and safety data from the FELIX trial. The therapy launches at a premium price, with streamlined onboarding due to no REMS requirement, and broad center rollout planned over the next year.
-
Regulatory review for obe-cel is on track, with strong pivotal data and a robust cash position supporting launch and pipeline expansion. Commercial readiness is advancing, with 30–36 centers expected at launch and a focus on operational execution.
-
Obe-cel, a CAR T therapy, is under FDA and European review, showing strong long-term survival and safety in ALL. Manufacturing and launch systems are in place, with broad US center coverage planned. Financially robust, the company is positioned for profitability and pipeline growth.
-
The session highlighted a CAR T platform with strong efficacy and safety in ALL, robust long-term remission data, and a differentiated manufacturing approach. Expansion into autoimmune diseases is underway, leveraging product safety and persistence.
-
Updated FELIX study data show 40% of adult ALL responders remain in remission at 21.5 months without transplant, with durable EFS and OS plateaus. Stem cell transplant did not improve outcomes, while ongoing CAR T persistence is key for long-term benefit. Commercial launch and regulatory filings are on track.